Board of Directors

Strategic and operational management is led by John Harris, CEO, while OBN is governed by a balanced Board of Directors.  We also draw on the views and experience of several advisory groups and panels.

OBN is governed by a balanced Board of Directors, whose members bring to the organisation significant commercial experience at the highest level across the pharma, biotech, medtech and financial sectors. The Company believes that the skills and experience of the Directors are of an appropriate mix to provide effective governance and management of the business.

The Board is responsible for organisation’s system of corporate governance and internal control and is accountable for all its activities. The Board reviews the operational performance of the organisation on a regular basis. The Board members are listed below and biographical details are available by clicking on the relevant links.

Its aim is to represent the interests of OBN’s Members through setting and reviewing its strategic focus, as well as to ensure the growth and development of a successful and sustainable organisation.

Sally_Waterman bw web May 2014 250x330
CHAIRMAN

SALLY WATERMAN

Sally Waterman joined PolyTherics in October 2009 as COO. Sally’s previous roles include Director of Research & Development at Protherics (now part of BTG) and KS Biomedix (acquired by Xenova), VP of Non-clinical Development at Vernalis and Director of Scientific Operations at Pharmakopius (since acquired by PRA).
Her early career was spent in regulatory affairs in GD Searle, Wyeth and Sterling Winthrop. Sally has been a member of several Boards, including Discerna, the first spin-out company from the Babraham Bioscience Technologies Limited. She has a BSc degree in Biological Sciences and obtained a PhD from the University of Reading for her research with Campylobacter jejuni.

JOHN HARRIS

CEO, OBN

John brings to OBN extensive leadership and managerial competence developed within well respected Blue-Chip, Governmental and SME organisations, specialised in the Life Sciences Sectors. Over his 30 years working in this space (including 14 years at CEO level), he has developed considerable experience and expertise within the pharmaceutical and medical technology arenas ranging through research, technical & commercial development, registration, manufacture, marketing, and sales.

Immediately prior to joining OBN he was involved in delivering Business and Export advice to UK Trade & Industry clients, assisting Life Science companies on growth strategies both domestically and abroad and was Managing Partner of Qube Associates, a specialist consultancy focusing on science-based SME’s.  Previous appointments include Managing Director of IPS Specials / Vertical Pharma Ltd (a cGMP, MHRA licensed manufacturer of ‘Special’ compounded pharmaceuticals), Managing Director of Key Organics Ltd (a leading manufacturer of chemical intermediates), Managing Director of Synerga Ltd (a start-up drug discovery venture) and Chief Executive Officer of TraceTag International Ltd (a biotech company specialising in the research, development and marketing of hi-tech diagnostics).

Dr Harris holds a BSc (Hons) in Biology from the University of Salford, a PhD in Biochemistry from the University of Southampton and a MBA from the University of Surrey.

John Harris
photo

MARK ANDERSON

Managing Partner, Anderson Law

Mark Anderson joined OBN as a non-executive director in August 2016. He is the managing partner of a 12-lawyer firm of solicitors based in Oxfordshire that specialises in intellectual property and commercial transactions. He has advised clients in the life-science sector since 1987. He is the chairman of the Board of Directors of BioLaw Europe FmbA, a Danish not-for-profit association, and chairman of the Intellectual Property Law Committee of the Law Society of England and Wales. He is a visiting professor at University College London and the convenor of an annual, 5-day course on IP transactions for practitioners that has won a UCL Provost’s Teaching Award.

DENISE GOODE

Director, QED Life Sciences

Denise Goode, previously from AstraZeneca’s Business Development team, has extensive financial, commercial and industry dealmaking experience. A biologist and chartered accountant, Denise has worked in a broad range of strategic and finance roles; has a track record of deal delivery; and bringing over a decade of both buy- and sell-side business development transaction expertise. She joined the Board of OBN in January 2014.

obn_bod_denise_goode
obn_bod_rod_cook

ROD COOK

BSc FCIPD, Partner, Biotech Personnel

Rod is an independent consultant offering a generalist HR service with a health care industry focus. He established Biotech Personnel in 1996 after 20 years in industry with companies including G D Searle and British Biotech.  He has assisted multiple hi tech companies with set up and on-going HR needs and has been involved with OBN almost since inception. Rod has a BSc (Hons) in Physics and Computing from the University of London. He is a Chartered Fellow of the Chartered Institute of Personnel and Development.

DAVID LASKOW-POOLEY

CEO, LondonPharma and Managing Director, Pharmafor

David has been involved with London Pharma since 2010.  He has enjoyed an extensive career in pharmaceuticals, diagnostics and devices commencing with GSK, Abbott, Life Technologies, Amersham International, and OSI Pharmaceuticals where he operated at Executive level.  He has experience in development, operations and commercial and general management.  More recently he has focused on start-ups initially spinning out Surface Therapeutics from Oxford University.  Now with London Pharma which is an early stage company with late stage products, repositioning molecules through its own sub-lingual spray delivery system.

obn_bod_david_pooley
Brian-photo2

BRIAN HARGREAVES

Independent Advisor, Private Equity

Brian Hargreaves is an independent advisor to Private Equity.

His career in Healthcare spans academia, Pharma, Venture Capital and Private Equity.  Following his early career as a Lecturer in Pharmacy at Manchester University, he had a series of commercial and international marketing roles with Smith Kline and French, Mundipharma, Wellcome, Glaxo Wellcome and with Astra Hässle where he led the commercialisation of the blockbuster product, Nexium.  In 1997, he moved to 3i plc in the innovative growth period of biotech Venture Capital.  More lately he originated several significant Growth Capital and Buyouts deals.

He currently advises selected Private Equity firms and spends a proportion of his time in the charity sector.

ROSS SOMMERVILLE

CEO, Lonestar Strategies Ltd

Ross Sommerville is CEO of Lonestar Strategies Ltd and is a business mentor and executive coach to companies in the lifescience sector.  He has held senior commercial roles within medtech: at ResMed Inc where he ran business teams across a wide range of European countries and, before that, at Baxter Healthcare Inc where he was European VP Marketing for its Blood Transfusion business.   In 2015, Ross spent 8 months as Interim CEO of OBN where he helped review the strategy of the organization and recruit a new, permanent CEO.  His background and early career is in economics where he worked for government in Australia as well as the OECD in Paris.  He holds an MBA from the AGSM (Sydney) and a Diploma in Executive Coaching from the Academy of Executive Coaching (London).

Ross